Ongoing HTAs by Avalia-t in Spain in March 2026

In March 2026, the Galician Agency for Health Technology Assessment (Avalia-t) is working on several HTAs, including in cardiovascular, dermatology, e-health, gastrointestinal, interventional radiology, robotic surgery, in-vitro diagnostics, peripheral vascular, neurology and neurosurgery, neuromodulation, and some other fields. 

Some examples are provided below:

• Antibiotic mesh in electronic cardiac devices;
• Extracorporeal shock wave therapy for the treatment of chronic skin wounds;
• Virtual reality exposure therapy in adults with specific phobias;
• Irreversible electroporation for liver metastasis of colorectal cancer;
• New robotic surgical platform in oncological digestive surgery;
• Early detection of graft damage in kidney and heart transplant recipients using donor-derived cell-free DNA;
• Update of the evaluation of the safety, clinical effectiveness, and cost-effectiveness of neonatal screening for beta-ketothiolase deficiency and classical galactosemia;
• Branched endovascular prostheses for the treatment of aortic arch pathology.

The full details in Spanish can be found here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.